Mark Cuban’s “Cost-Plus” Drugs: The Pricing Promise—and the Spread Problem Nobody’s Explaining Clearly
The loudest claim in healthcare right now isn’t about clinical outcomes. It’s about pricing mechanics.
Mark Cuban’s Cost Plus Drugs model has become …

Cubans’ “cost-plus” model is proving a point: generics and brands don’t play the same game.
For years, the debate around drug pricing has sounded like a single problem with a single solution. But the closer you look, the more it becomes clear that the …

Drug pricing is a black box—until you look at the math.
Most people hear “cost-plus” and assume it’s a slogan. But the real story is far less political and far more mechanical: how drug prices are built, what’s included, and what’s quietly left out. …

Mark Cuban’s generic-drug play isn’t just another “disruption” story—it’s a stress test for the entire pharmaceutical value chain.
Here’s the hook: when generics move faster than incumbents expect, the first casualties aren’t always the drugmakers. The…

Biotech hiring isn’t just about growth. It’s often about patent strategy.
Here’s the agitation: when you see a sudden spike in job postings—IP counsel, licensing managers, BD leads, regulatory affairs, even “business development” roles that look generi…

Pharma’s “patent cliff” isn’t a cliff anymore—it’s a business model.
For years, investors have treated patent expirations like gravity: once exclusivity ends, generic competition arrives, prices fall, and revenue trajectories bend sharply downward. But…

Drug pricing transparency is having a moment. In policy circles, it’s become the go-to “fix”: publish more data, shine a brighter light, and—somehow—prices will behave.
But the argument that transparency is inherently pro-patient is incomplete. In fact…

Mark Cuban’s Cost-Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now
The headline debate—Cost-Plus drugs vs. Big Pharma—is easy to reduce to politics, personalities, or pricing outrage. But the real story is more operational…

Pharma doesn’t “miss” patent dates. It just doesn’t miss them publicly.
Behind the scenes, companies run a relentless calendar—one that tracks IND filings, NDA milestones, regulatory review clocks, and the precise triggers that can unlock patent term e…

Pharma’s quiet superpower isn’t just R&D—it’s the calendar.
In the race to extend exclusivity, the most valuable asset often isn’t a molecule. It’s a date.
A new post from DrugPatentWatch pulls back the curtain on how pharmaceutical companies tra…